Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Update Il y a 4 ans
Reference: NCT01305460

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients.


Inclusion criteria

  • myelodysplastic syndrome

Links